A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues.
Nature communications
confidence
Key findings
SenMayo gene set identifies senescent cells across tissues and species; not a clinical endpoint study for dasatinib.
View source on PubMed (PMID 35974106) ↗
- Sample size
- Not reported
- Population
- Human and murine bone marrow/bone scRNA-seq data; aged human bone biopsies; mice with genetic senescent cell clearance; humans with pharmacological senescent cell clearance
- Dosing
- Not reported
- Duration
- Not reported
- Route
- Not reported
- Blinding
- not_reported
- Controls
- none
- Drug class
- senolytic
Full abstract
Although cellular senescence drives multiple age-related co-morbidities through the senescence-associated secretory phenotype, in vivo senescent cell identification remains challenging. Here, we generate a gene set (SenMayo) and validate its enrichment in bone biopsies from two aged human cohorts. We further demonstrate reductions in SenMayo in bone following genetic clearance of senescent cells in mice and in adipose tissue from humans following pharmacological senescent cell clearance. We next use SenMayo to identify senescent hematopoietic or mesenchymal cells at the single cell level from human and murine bone marrow/bone scRNA-seq data. Thus, SenMayo identifies senescent cells across tissues and species with high fidelity. Using this senescence panel, we are able to characterize senescent cells at the single cell level and identify key intercellular signaling pathways. SenMayo also represents a potentially clinically applicable panel for monitoring senescent cell burden with aging and other conditions as well as in studies of senolytic drugs.